Dual mechanism MAPK inhibitors bind MAPKs

Stable Identifier
R-HSA-9657603
Type
Reaction [binding]
Species
Homo sapiens
Compartment
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

A number of 'dual mechanism' MAPK inhibitors are in preclinical or clinical trials (reviewed in Roskoski, 2019). Dual mechanism inhibitors, including the ATP-competitive inhibitors SCH772984 and MK-8353, bind to the unphosphorylated MAPK and prevent both its own kinase activity and its phosphorylation by MAP2Ks (Morris et al, 2013; Deng et al 2014; Chaikuad et al, 2014; Boga et al, 2018; Moschos et al, 2019; reviewed in Samatar and Poulikakos, 2014). MAPK inhibitors offer the potential to mitigate the development of resistance to RAF and MAP2K inhibitors, which often involves reactivation of MAPK-dependent signaling. As a result, MAPK inhibitors are frequently used in combination with RAF and MAP2K-directed therapeutics (reviewed in Samatar and Poulikakos, 2014; Roskoski, 2019).

Literature References
PubMed ID Title Journal Year
25195011 A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics

Chaikuad, A, Tacconi, EM, Zimmer, J, Liang, Y, Gray, NS, Tarsounas, M, Knapp, S

Nat. Chem. Biol. 2014
30034615 MK-8353: Discovery of an Orally Bioavailable Dual Mechanism ERK Inhibitor for Oncology

Boga, SB, Deng, Y, Zhu, L, Nan, Y, Cooper, AB, Shipps, GW, Doll, R, Shih, NY, Zhu, H, Sun, R, Wang, T, Paliwal, S, Tsui, HC, Gao, X, Yao, X, Desai, J, Wang, J, Alhassan, AB, Kelly, J, Patel, M, Muppalla, K, Gudipati, S, Zhang, LK, Buevich, A, Hesk, D, Carr, D, Dayananth, P, Black, S, Mei, H, Cox, K, Sherborne, B, Hruza, AW, Xiao, L, Jin, W, Long, B, Liu, G, Taylor, SA, Kirschmeier, P, Windsor, WT, Bishop, R, Samatar, AA

ACS Med Chem Lett 2018
23614898 Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors

Morris, EJ, Jha, S, Restaino, CR, Dayananth, P, Zhu, H, Cooper, A, Carr, D, Deng, Y, Jin, W, Black, S, Long, B, Liu, J, Dinunzio, E, Windsor, W, Zhang, R, Zhao, S, Angagaw, MH, Pinheiro, EM, Desai, J, Xiao, L, Shipps, G, Hruza, A, Wang, J, Kelly, J, Paliwal, S, Gao, X, Babu, BS, Zhu, L, Daublain, P, Zhang, L, Lutterbach, BA, Pelletier, MR, Philippar, U, Siliphaivanh, P, Witter, D, Kirschmeier, P, Bishop, WR, Hicklin, D, Gilliland, DG, Jayaraman, L, Zawel, L, Fawell, S, Samatar, AA

Cancer Discov 2013
30794926 Targeting ERK1/2 protein-serine/threonine kinases in human cancers

Roskoski, R Jr

Pharmacol. Res. 2019
25313996 Discovery of novel, dual mechanism ERK inhibitors by affinity selection screening of an inactive kinase

Deng, Y, Shipps, GW, Cooper, A, English, JM, Annis, DA, Carr, D, Nan, Y, Wang, T, Zhu, HY, Chuang, CC, Dayananth, P, Hruza, AW, Xiao, L, Jin, W, Kirschmeier, P, Windsor, WT, Samatar, AA

J. Med. Chem. 2014
29467321 Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors

Moschos, SJ, Sullivan, RJ, Hwu, WJ, Ramanathan, RK, Adjei, AA, Fong, PC, Shapira-Frommer, R, Tawbi, HA, Rubino, J, Rush, TS, Zhang, D, Miselis, NR, Samatar, AA, Chun, P, Rubin, EH, Schiller, J, Long, BJ, Dayananth, P, Carr, D, Kirschmeier, P, Bishop, WR, Deng, Y, Cooper, A, Shipps, GW, Moreno, BH, Robert, L, Ribas, A, Flaherty, KT

JCI Insight 2018
25435214 Targeting RAS-ERK signalling in cancer: promises and challenges

Samatar, AA, Poulikakos, PI

Nat Rev Drug Discov 2014
Participants
Participant Of
Orthologous Events
Authored
Reviewed
Created
Cite Us!